This analog, after activating GLP 1 receptors, accelerated BC in vitro and in vivo via the NADPH oxidase 4/reactive oxygen species/VEGF signaling pathway, whereas exendin (9–39), a GLP 1 receptor antagonist, blocked the effects mediated by liraglutide [86]. Here, GLP1R is linked to breast cancer.